SC
NVAX icon

Scotia Capital’s Novavax NVAX Stock Holding History

Scotia Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,122
Closed -$96.2K – 870
2024
Q1 		$96.2K Buy
+20,122
New +$93.3K ﹤0.01% 794
2022
Q1 		– Sell
-2,617
Closed -$374K – 920
2021
Q4 		$374K Sell
2,617
-12,493
-83% -$2.15M ﹤0.01% 692
2021
Q3 		$3.13M Buy
15,110
+5,369
+55% +$1.18M 0.02% 315
2021
Q2 		$2.07M Buy
+9,741
New +$1.78M 0.02% 389

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Scotia Capital's NVAX Position: Q2 2024 in Review

Scotia Capital sold out of Novavax (NVAX) in Q2 2024, closing a stake of 20,122 shares — an estimated $96.2K sold.

Scotia Capital first reported a position in NVAX in Q2 2021 and held it in 4 quarters. The position peaked at $3.13M in Q3 2021. 229 funds tracked by Wall St. Rank hold NVAX as of Q2 2024.

  • Scotia Capital reported no remaining Novavax position as of Q2 2024 after selling out during the quarter.
  • Scotia Capital sold 20,122 Novavax shares in Q2 2024, an estimated $96.2K.
  • Scotia Capital first reported a position in Novavax in Q2 2021 and held it in 4 quarters.
  • Scotia Capital's Novavax position peaked at $3.13M in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Novavax as of Q2 2024.

Based on Scotia Capital's 13F filing for Q2 2024, filed 14 Aug 2024.